Other than PD-L1 expression in non-small cell lung cancer (Pawelczyk et al., 2019), gastric cancer (Fuchs et al., 2018), and cervical cancer (Chung et al., 2019), and two tumor agnostic markers (microsatellite instability (Zhao et al., 2019) and tumor mutational burden (Huang et al., 2021)), no biomarker has consistently aided the decision-making process with ICIs. The gene discussed is CD274; the disease is neoplasm.